- Home
- SABR vs SYRE Comparison
SABR vs SYRE Comparison
Compare SABR & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABR
- SYRE
- Stock Information
- Founded
- SABR 2006
- SYRE 2013
- Country
- SABR United States
- SYRE United States
- Employees
- SABR N/A
- SYRE N/A
- Industry
- SABR Computer Software: Programming Data Processing
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- SABR Technology
- SYRE Health Care
- Exchange
- SABR Nasdaq
- SYRE Nasdaq
- Market Cap
- SABR 1.2B
- SYRE 1.1B
- IPO Year
- SABR 2014
- SYRE 2016
- Fundamental
- Price
- SABR $1.85
- SYRE $15.77
- Analyst Decision
- SABR Buy
- SYRE Buy
- Analyst Count
- SABR 5
- SYRE 5
- Target Price
- SABR $4.12
- SYRE $55.00
- AVG Volume (30 Days)
- SABR 6.4M
- SYRE 414.7K
- Earning Date
- SABR 10-30-2025
- SYRE 11-06-2025
- Dividend Yield
- SABR N/A
- SYRE N/A
- EPS Growth
- SABR N/A
- SYRE N/A
- EPS
- SABR N/A
- SYRE N/A
- Revenue
- SABR $3,010,157,000.00
- SYRE N/A
- Revenue This Year
- SABR N/A
- SYRE N/A
- Revenue Next Year
- SABR $4.17
- SYRE N/A
- P/E Ratio
- SABR N/A
- SYRE N/A
- Revenue Growth
- SABR 6.13
- SYRE N/A
- 52 Week Low
- SABR $1.69
- SYRE $10.91
- 52 Week High
- SABR $4.63
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- SABR 41.43
- SYRE 42.02
- Support Level
- SABR $1.70
- SYRE $15.80
- Resistance Level
- SABR $1.83
- SYRE $17.58
- Average True Range (ATR)
- SABR 0.07
- SYRE 0.74
- MACD
- SABR 0.06
- SYRE -0.11
- Stochastic Oscillator
- SABR 84.21
- SYRE 5.85
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company announced a planned sale of its growing hotel IT solutions division (9% of revenue) to TPG for $960 million in net proceeds, which is scheduled to close in late 2025. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.